Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Barclay CTA Index gains +2.64% in May (+1.33% YTD)

Wednesday, June 20, 2012

Sol Waksman
Opalesque Industry Update - Managed futures gained 2.64% in May according to the Barclay CTA Index compiled by BarclayHedge. The Index is up 1.92% year-to-date.

“The risk-off trade which started to gain momentum in April moved into high gear in May, allowing CTAs that were properly positioned to have a profitable month,” says Sol Waksman, founder and president of BarclayHedge.

“Signs of slowing in the US and China, coupled with fears of financial contagion in Europe, drove prices for equities and commodities sharply lower while the US dollar and bond prices in ‘safe’ countries rallied strongly.”

Six of Barclay’s eight CTA indices had gains in May. The Diversified Traders Index and the Systematic Traders Index both jumped 3.47%, Financial & Metals Traders were up 2.26%, and Currency Traders added 1.57%.

“The profitable trends in May were set in motion in April, giving diversified and systematic traders ample opportunity to get on board,” says Waksman.

“The Barclay Diversified Traders Index and Systemic Traders Index both recorded respectable gains in May, and now have a small positive return year-to-date.”

On the losing side, the Agricultural Traders Index was down 2.03%, and Discretionary Traders gave up 0.79% in May.

“When markets become over-extended, discretionary traders oftentimes lose out, whereas these conditions present a more profitable scenario for systematic traders,” says Waksman The Barclay BTOP50 Index, which measures performance of the largest CTAs, gained 1.84% in May. The BTOP50 is now up 1.13% for the year. Full performance table: Source
PD

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for